| 1<br>2<br>3  | Acute and Subacute Ischemia of Lower Limbs: Angiographyand Peripheral Hemodynamics.<br>Bulvas M, Sommerová Z.  |
|--|--|
| 4  |  |
| 5  | Acute and Subacute Ischemia of Lower Limbs:  |
| 6  | Angiography and Peripheral Hemodynamics  |
| 7  |  |
| 8  | Running title: Acute and subacute limb ischemia  |
| 9<br>10<br>11  | Miroslav Bulvas, MD. PhD. Assoc. Prof.<br>Zuzana Sommerová, MD. PhD.   |
| 12<br>13<br>14<br>15<br>16   | Affiliations:<br>Miroslav Bulvas, Department of Surgery, Division of Angiology, University Hospital<br>Královské Vinohrady, Third Faculty of Medicine, Charles University (address: Šrobárova 50,<br>100 34, Prague 10, Czech Republic)  |
| 17<br>18<br>19<br>20<br>21   | Zuzana Sommerová, Center for Cardiovascular Prevention, First Faculty of Medicine and<br>Thomayer Hospital, Charles University (address: Vídeňská 800, 140 59 Prague 4, Czech<br>Republic), email: <u>zuzanasommerova@mybox.cz</u>   |
| 22<br>23   | Corresponding author: Miroslav Bulvas, email: <u>bulvasm@seznam.cz</u>   |
| 24   | <u>miroslav.bulvas@lf3.cuni.cz</u>   |
| 25   | phone: +420 603426473  |
| 26<br>27   | address: U Michelského mlýna 35, 140 00 Prague 4,<br>Czech Republic  |
| 28   | ORCID iD: 0000-0003-4211-6696  |
| 29<br>30<br>31<br>32<br>33<br>34<br>35<br>36<br>37<br>38<br>37<br>38<br>39<br>40<br>41<br>42 | <ul> <li><u>Acknowledgments</u> <ul> <li>The authors thank Candance McClure (NAMSA, Toledo, OH, USA) and Marian Rybář (MATSTAT, Prague, Czech Republic) for statistical expertise.</li> </ul> </li> <li><u>Declaration of Conflicting Interests:</u> The authors have no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</li> <li><u>Funding</u> <ul> <li>The authors recieved no financial support for the research, authorship, and/or publication of this article.</li> </ul> </li> </ul> |

| 44 | ABSTRACT |
|----|----------|
| 45 |          |

46 Objective: To identify pretreatment characteristics related to ischemia severity and symptoms
47 duration in patients with acute (ALI) and subacute lower limb ischemia (SLI).

Methods: Comparative study, a part of prospective, single-arm, single-center trial of 316
consecutive patients with threatened extremities (all-comers, mean age: 70.9±12.0 years,
range: 23-96; 184 men) of whom 99. 4 % suffered from acute or subacute supratibial
occlusions (target occlusions).
Results: Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented
in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The

value of ABI related to the number of occluded tibial arteries. Occlusion locations associated
with ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Furthermore, ALI
subjects presented additional infrapopliteal occlusion (acute and/or subacute), smaller number

57 of patent tibial arteries and lower ABI.

#### 58 **Conclusion:**

Anatomically, the most important factor related to the ischemia severity and symptoms duration was the status of infrapopliteal vascular bed. The number of acutely, subacutely or chronically occluded tibial vessels was related to clinical categories of ALI and SLI and to ABI. This suggests that tibial reperfusion can be essential for the salvage of threatened limb and should be always considered.

- 64
- 65
- 66 67
- .
- 68
- 69
- 70

#### 71 <u>INTRODUCTION</u>

Acute lower limb ischemia (ALI) is a critical vascular emergency that endangers the affected extremity and puts the patient's life at risk. It is defined as a sudden decrease in or worsening of limb perfusion that has been present for 14 days or less and causing a potential threat to limb viability<sup>1,2</sup>.

The clinical presentation of ALI is not single and varies from viable to irreversibly damaged extremity. The limb can be threatened immediately after the symptoms origin or later when ischemia progresses, steadily or in steps. The fact that suddenly developed ischemia can escalate during the time period longer than 2 weeks, led many authors to use the term "subacute limb ischemia" (SLI) to distinguish the unstable and developing condition from the chronic, stable ischemic status. The guidelines<sup>3,4</sup> defined SLI by symptoms duration longer than 14 days, and lasting up to 3 months.

The pre-treatment factors, reported in the literature<sup>5,6</sup> to influence the mortality and amputation rates were high age, female gender, non-Caucasian race, comorbidities (diabetes, malignancy, neurological disorders, coronary heart disease, congestive heart disease), multilevel occlusion, more proximal occlusions, limb ischaemia severity, treatment risk and urgency, tissue damage, repeated ALI attacks, absence of early anticoagulation and delay in diagnosis and revascularization. However, their role and incidence may differ in patients with different clinical presentation.

Because the same initial treatment techniques (open surgery, catheter-directed thrombolysis, mechanical thrombectomy) are used in patients with ALI or SLI<sup>7</sup>, different number of patients with SLI and those with ALI categorized as type I (viable extremity), IIA (marginally threatened) or IIB (immediately threatened) have been often grouped in ALI cohorts in studies to date analyzing surgical and/or endovascular treatment outcomes. To understand whether such a grouping can affect the overall results and comparability among the studies, it is important to learn more about characteristic of individual clinical categories.

4

97 Closer knowledge is necessary for better understanding the high mortality and amputation
98 rates, and the factors associated with or responsible for clinical presentation, serious events
99 and technical failure of therapeutic intervention.

100 The aim of this study was to identify the relations of ischemia severity and/or 101 symptoms duration with age, gender, comorbidities, clinical presentation, arterial occlusion 102 aetiology, vascular anatomy and peripheral hemodynamics in patients with threatened lower 103 extremity due to ALI (IIA, IIB) or SLI. Specifically, we focused on the role of infrapopliteal 104 arterial patency in 316 patients (all-comers) of whom 99. 4 % primarily suffered from acute 105 or subacute supratibial occlusions (target occlusions).

#### 106 MATERIAL AND METHODS

107 Our study was a single-centre, prospective, single-arm trial performed during the time 108 interval 2009–2015 with two main goals. The first part documented the efficacy, safety and 109 applicability of endovascular removal of occlusive material as the initial treatment in patients 110 with limb threatening ALI and SLI. It was already published <sup>8</sup>.

In this report, we focused on pre-treatment difference between clinical categories (ALI vs. SLI, ALI IIB vs. ALI IIA, females vs. males, thrombotic occlusion vs. embolism). We compared demographic data, frequencies of risk factors and comorbidities, clinical data, ankle-brachial pressure index (ABI) and vascular anatomy characteristics (Table 1, 2).

115 The target lesion and vascular anatomy information was obtained by digital 116 subtraction angiography in all patients. No therapeutic interventions were performed or tested 117 in this part of the study.

The study included 316 consecutive patients (all-comers, 184 men, mean age:  $70.9 \pm$ 119 12.0 years): 202 subjects with ALI (114 men, mean age:  $72.6 \pm 12.2$ , mean symptoms 120 duration:  $4.13 \pm 4.47$  days; 146 patients categorized as IIB of the Rutherford classification for 121 acute limb ischaemia<sup>2</sup>; 56 patients of the category IIA) and 114 patients with SLI (70 men,

5

mean age:  $67.9 \pm 10.9$  years; mean symptoms duration:  $44.3 \pm 27.3$  days). SLI patients were categorized on the basis of the Rutherford classification for chronic limb ischemia <sup>2</sup> (38 patients: category 3; 50 patients: category 4; 26 patients: category 5). Critical limb ischemia was diagnosed in 74 patients with SLI according to established guidelines <sup>1,9,10</sup>.

Target, supratibial occlusions (acute or subacute) were located in aortoiliac arterial segment, femoropopliteal segment, deep femoral artery, bypasses (aortofemoral, femoropopliteal, femorofemoral) and leg of bifurcation stentgraft (Table 2) in 99.4 % of patients. Isolated infrapopliteal occlusions were detected in two patients (0.6 %).

Occlusion cause was determined on the basis of clinical manifestation, angiographic findings<sup>11</sup>, resistance to guidewire penetration and occurrence of underlying lesion after the clot removal. Thrombotic occlusion was diagnosed in 256 (81.0 %), and embolism in 60 (19.0 %) patients.

134 The University Hospital Královské Vinohrady and the Third Medical Faculty of the 135 Charles University Centralized Institutional Review Board approved the study protocol and 136 informed consent form (identifier: EK/IV-2/2009). The study was conducted in accordance with Declaration of Helsinki, and all patients provided written informed consent. The trial was 137 138 registered with the International Standard Randomized Controlled Trials Number registry 139 (ISRCTN 154967770). The inclusion criteria allowed enrolment of adult patients with ALI 140 (symptoms duration  $\leq$  14 days) or SLI (symptoms duration >14 days and  $\leq$  3 months), severe 141 claudication, ischemic rest pain, sensorimotor deficit and/or tissue defects. Patients presented 142 from a variety of sources - overflow from other urban institutions, remote community 143 hospitals, physician referral, and self-presenting. The exclusion criteria were irreversible 144 ischemia and viable extremity.

145 Statistical analysis: continuous data are presented as the mean ± standard deviation
146 (SD). Categorical data are given as the number (percentage). Continuous variables were

6

| 147 | compared using a paired or unpaired t test or Wilcoxon rank sum test, as appropriate.         |
|-----|---|
| 148 | Categorical variables were analyzed using a 2 -sided chi-square or Fischer exact test, as     |
| 149 | appropriate. For analysis of variance (ANOVA), Welch's test for unequal sample sizes was      |
| 150 | used. The threshold of statistical significance was $p < 0.05$ . Statistical analyses were    |
| 151 | performed using SAS software (version 9.4; SAS Institute, USA) and STATSOFT software          |
| 152 | for Welch's test (Statistica, version 10, USA).   |
| 153 |   |
| 154 | RESULTS   |
| 155 | Anatomy   |
| 156 | The presence of acute or subacute supratibial arterial occlusions was documented in           |
| 157 | 314 (99.4 %) of 316 patients with threatened lower limbs due to ALI and SLI. Mean length      |
| 158 | of supratibial occlusion was greater in group with ALI (244.6 mm) vs. SLI (202.0 mm),         |
| 159 | p=0.0159 and in patients with thrombotic cause of the occlusion (246.6 mm) vs. embolism       |
| 160 | (155.0 mm, p<.0001).  |
| 161 | The most frequently occluded (acutely or subacutely) locations were the                       |
| 162 | femoropopliteal segment (in 73.1 % of 316 patients) and femoropopliteal bypass (22.8%).       |
| 163 | Significant difference in frequency of femoropopliteal segment and femoropoplital bypass      |
| 164 | occlusion was not documented between patients with ALI vs. SLI and ALI IIB vs. ALI IIA        |
| 165 | (Table 1).  |
| 166 | The aortoiliac segment occlusion was detected in 11.1 % of all patients, with higher          |
| 167 | incidence in those with ALI (13.9 %) vs. SLI (6.1 %, p=.0401) (Table 2). The incidence of the |
| 168 | deep femoral artery occlusion was higher in patients with ALI vs. SLI (12.9 vs. 5.3 %,        |
| 169 | p=0.0332), embolism vs. thrombosis (23.3 vs. 7.0 %, p=.0006) and females vs. males (15.2      |
| 170 | vs. 6.5%, p=.0142) (Table 2).   |

7

| 171 | Infrapopliteal occlusion (acute or subacute) additional to occlusion located                  |
|-----|---|
| 172 | supratibially was documented in 61.7 % of all patients (ALI + SLI) with higher frequency in   |
| 173 | patients with ALI (68.3 %) vs. SLI (50.0 %, p=.0017), ALI IIB (72.6 %) vs. ALI IIA (57.1 %,   |
| 174 | p=.0427) and embolism (73.3 %) vs. thrombosis (59.0 %, p=.0403) (Table 2, 4, 6).              |
| 175 | Infrapopliteal occlusion (acute, subacute and chronic; segmental or total) in one, two        |
| 176 | or three tibial vessels was detected in 86.1 % of 316 patients with significant difference    |
| 177 | between ALI (90.6 %) vs. SLI (78.1 %, p=.0036) subjects. All tibial vessels occluded were     |
| 178 | documented in 33.3 % of SLI and 62.4 % of ALI patients (p=.0001) (Fig. 1).                    |
| 179 | Higher mean number of patent (without acute, subacute or chronic occlusions) tibial           |
| 180 | vessels was detected in patients with SLI (1.3) vs. ALI (0.7, p<.0001), ALI IIA (1.4) vs. ALI |
| 181 | IIB (0.4, p<.0001), thrombosis (1.0) vs. embolism (0.4, p<.0001) (Table 2, 4, 6).             |
| 182 | Higher incidence of the femoropopliteal segment occlusion was established in subjects         |
| 183 | with embolism (95.0 %) vs. thrombosis (68.0 %, p<.0001) and in female group (79.5 %) vs.      |
| 184 | males (68.5 %, p=.0296).  |
| 185 | Higher frequency of the femoropopliteal bypass occlusion was detected in the male             |
| 186 | group (28.8 %) vs. females (14.4 %, p=.0027) and patients with thrombotic occlusion (27.7     |
| 187 | %) vs. embolism (1.7 %, p<.0001) (Table 6, 7).  |
| 188 |   |
| 189 | Ankle-brachial index  |
| 190 | Generally, the mean ABI was low (0.1) in the group of patients with ALI and SLI               |

before treatment. Its value was higher in patients with SLI (0.22) vs. those with ALI (0.08,
p<.0001), in subjects with ALI IIA (0.2) vs. ALI IIB (0.0, p<.0001) and in patients with</li>

thrombosis (0.14) vs. embolism (0.07, p=.0016) (Table 2, 4, 6). In subgroup with ABI ranged

194 from 0.0 to 0.1, the patients with ALI were in majority (71.2 %). Patients with SLI dominated

in the subgroups with ABI value from 0.2-0.5 (Fig 2).

8

The value of ABI significantly correlated (p<.001) with the number of patent calf</li>vessels in subjects with ALI or SLI (Fig. 3,4).

198

#### 199 Target occlusion origin: embolism vs. thrombosis

200 Embolism as the cause of target supratibial occlusion was detected in 19 % of patients

201 with ALI+SLI. This cause was more frequent in patients with ALI (24.8 %) vs. SLI ((8.8 %,

202 p=.0005), ALI IIB (28.8%) vs. ALI IIA (14.3 %, p=.0442) and in females (29.5 %) vs. males

203 (11.4 %, p<.0001) (Table 2, 3, 7).

In comparison with thrombotic lesions, the embolic occlusions were shorter in average (155 vs. 246.6 mm, p<.0001) and they were localized more frequently in the femoropopliteal segment (95.0 vs. 68.0 %, p<.0001) and/or the deep femoral artery (23.3 vs. 7.0 %, p=.0006) (Table 6).

In patients with embolic supratibial closure, higher number (73.3 vs. 59.0 %, p=.0403) of those with additional occlusions (acute, subacute, chronic; embolic or thrombotic) located infrapopliteally was detected. Additionally, these subjects presented lower number of patent calf vessels (0.4 vs. 1.0, p<.0001) and lower ABI (0.07 vs. 0.14, p=.0016).

Embolism was also associated with higher age (73.7 vs. 70.2 years, p=.0054), higher incidence of female gender (65.0 % vs. 36.3 %, p<.0001), cardiac disease (61.7 vs. 37.5 %, p=.0008), arrhythmias (51.7 vs. 19.5 %, p<.0001), ALI (83.3 vs. 59.4 %, p=.0005) and ALI IIB (84.0 vs. 68.4 %, p=.0442).

On the other hand, patients with thrombotic occlusion presented more frequent male gender (63.7 vs. 35 %, p<.0001), positive smoking history (59.8 vs. 31.7 %, p<.0001), SLI (40.6 vs. 16.7 %, p=.0005), ALI IIA (31.6 vs. 16 %, p=.0442), claudication (32.4 vs. 15 %, p=.0071), critical limb ischaemia (26.6 vs.10 %, p=.0062), tissue defect (17.2 vs. 5 %, p=.0151), in-stent occlusion (27.7 vs. 5 %, p<.0001), femoropopliteal bypass occlusion (27.1

9

vs. 1.7 %, p<.0001) higher number of patent calf vessels (1.0 vs. 0.4, p<.0001) and higher</li>
ABI (0.14 vs. 0.07, p=.0016) (Table 5,6).

223

#### 224 *Risk factors and concomitant disease*

225 Comparison between patients with SLI and ALI detected significantly higher 226 frequency of the smoking history (64.0 vs. 49.0 %, p=.0134), claudication (53.5 vs. 15.3 %, 227 p<.0001) and tissue defect (22.8 vs.10.4 %, p=.0047). The ALI patients were older (mean age: 228 72.6 vs. 67.9 years, p=.0005), with longer target lesion (mean length: 244.6 vs. 202.0 mm, 229 p=.0159), higher frequency of rest pain (83.7 vs. 57.9 %, p<.0001), embolism (24.8 vs. 8.8 %, 230 p=.0005), arrhythmias (30.7 vs. 16.7 %, p=.0071). A higher statistical trend toward increased 231 incidence of cardiac disease (46.0 vs. 35.1 %, p=.0749), cerebrovascular disease (28.2 vs.19.3 232 %, p=.0809) and renal insufficiency (26.7 vs. 17.5 %, p=.0726) was detected in ALI subjects 233 (Table 1,2).

234 Comparison between ALI patients with immediately (IIB) and marginally (IIA) 235 threatened extremities detected significantly higher frequency of diabetes (36.3 vs. 21.4 %, p=.0452), rest pain (91.8 vs. 62.5 %, p<.0001), embolism (28.8 vs. 14.3 %, p=.0442) in II B 236 237 subjects, together with lower mean number of patent calf vessels  $(0.4\pm0.9 \text{ vs. } 1.4\pm1.1,$ p<.0001), ankle-brachial index (0.0 $\pm$ 0.1 vs. 0.2 $\pm$ 0.2, p<.0001) and shorter mean duration of 238 239 the ischaemic symptoms (3.1 vs. 6.8 days, p=.0004). Patients with ALI IIB also presented 240 higher incidence of the cerebrovascular disease (32.2 vs. 17.9 %, p=.0543) and the renal 241 insufficiency (26.7 vs. 17.5 %, p=.0726), but those differences were beyond the statistical 242 significance (Table 3,4).

Subjects with ALI IIA presented higher frequency of smoking history (60.7 vs. 44.5
%, p=.0425), hyperlipidaemia (50.0 vs. 32.9 %, p=.0344), claudication (39.3 vs. 6.2 %,

10

| 245 | p<.0001) and thrombosis (85.7 vs. 71.2 %, p=.0442+) as the cause of target occlusion (Table |
|-----|---|
| 246 | 3, 4).  |

247

#### 248 Gender: Females vs. males

249 Female gender was associated with higher mean age (75.1 vs. 67.9 years, p<.0001), 250 higher incidence of hypertension (81.1 vs. 70.1 %, p=.0355), arrhythmias (34.8 vs. 19.0 %, 251 p=.0017) and embolism (29.5 vs. 11.4 %, p<.0001) as the cause of target arterial occlusion. 252 Additionally, the occlusion was more frequently located in the femoropopliteal arterial 253 segment (79.5 vs. 68.5 %, p=.0296) and the deep femoral artery (15.2 vs. 6.5 %, p=.0142) in 254 this subgroup. Male subgroup presented more frequent smoking history (67.4 vs. 36.4 %, 255 p<.0001), renal insufficiency (27.7 vs. 17.4 %, p=.0429), tissue defect (18.5 vs. 9.8 %, 256 p=.0375), thrombotic cause of the occlusion (88.6 vs. 70.5 %, p<.0001) and femoropopliteal 257 bypass occlusion (28.8 vs. 14.4 %, p=.0027). A higher statistical trend in favour of 258 claudication (33.2 vs. 23.5 %, p=.0785) was also detected in this subgroup (Table 7).

259

#### 260 Clinical presentation

261 Comparison between ALI patients with immediately (IIB) and marginally (IIA) threatened extremities detected significantly shorter mean duration of the ischaemic 262 263 symptoms (3.1 vs. 6.8 days, p=.0004). The incidence of tissue defects was higher in males 264 (18.5 % vs. 9.8 %, p=.0375), SLI vs. ALI (22.8 .vs 10.4 %, p=.0047), patients with 265 thrombosis vs. embolism (17. 2 vs. 5.0 %, p=.0151). The rest pain occurred more frequently 266 in ALI group (83.7 % vs. 57.9 %, p<.0001), and in ALI IIB vs. ALI IIA (91.8 vs. 62.5 %, 267 p<.0001). The claudication was detected in 53.5 % of subjects with SLI (vs. 15.3 % in ALI, 268 p<.0001), 39.3 % of ALI IIA (vs. 6.2 % in ALI IIB, p<.0001) and in patients with thrombosis 269 (32.4 %) vs. embolism (15.0 %, p=.0071) (Table 1,3,5,7).

#### 270 <u>DISCUSSION</u>

271 Ischaemia severity, symptoms duration and their progression in time vary with the 272 grade and dynamics of blood flow deterioration. Vessel anatomy before ALI attack, site and 273 cause of acute arterial occlusion, collateral development, embolus fragmentation and its 274 displacement to the peripheral branches, thrombosis progression, runoff quality and 275 antithrombotic therapy are the factors influencing clinical presentation of ALI. Together with 276 serious comorbidities, they affect periprocedural, early and long-term treatment outcomes, 277 morbidity, mortality and amputation rates. Detailed angiography description and pre-278 treatment ABI data were often not presented in the study reports dedicated to surgical and/or 279 endovascular therapy of ALI. Thus, the correlation of ischaemic symptoms and their duration 280 with the limb hemodynamics and vascular anatomy is difficult or impossible from the 281 literature.

282 In retrospective analysis of 160 ALI patients (symptoms duration 7 days or less, 13 % 283 embolic and 87 % thrombotic occlusions, 75 % clinical category II) managed with 186 intraarterial thrombolytic procedures, McNamara and colleagues<sup>12</sup> correlated angiographic 284 285 patterns with clinical severity of ischemia. They based the angiographic categorization on the 286 number of occluded arterial segments (common iliac, external iliac, common femoral, 287 superficial femoral, popliteal, trifurcation, bypass grafts), presence of visible patent distal 288 vessels, existence of patent collateral vessels, and the occurrence of stenoses involving inflow, 289 collateral, or outflow vessels. Clinical category "viable" (I) correlated with single-segment 290 occlusion, patent collaterals and distal vessels. Patients requiring blood to flow through two 291 contiguous collateral beds to supply distal vessels or with single occlusion combined with 292 stenosis of the adjacent inflow, outflow or collateral vessel correlated with the clinical 293 category "threatened" (II). Occlusions of more than two segments with distal propagation that 294 occluded the distal vascular bed correlated with the clinical category "irreversible" (III).

12

Severity of ischemia and extent of the occlusion correlated with death and amputation rate at30 days.

297 In their study of 45 patients with embolic occlusions managed by thrombolysis, Huettl and Soulen<sup>13</sup> detected no patent calf vessels in 56 % of patients, one calf vessel was patent in 298 299 22 %, two in 7 % and three in 16 % of patients before treatment. Those numbers are close to 300 our data. Using thrombolysis and additional endovascular techniques for treatment of non-301 embolic ALI in 119 patients (72 % grafts, 68 % category I), Kashyap and associates<sup>14</sup> 302 detected multisegmental thrombosis in 16 % and tibial thrombosis in 22 % of patients. Distal 303 occlusions beyond the reach of the rheolytic catheter limited the treatment in 57 % of 86 patients with ALI or SLI in the study of Kasirajan et al<sup>15</sup>. The need for distal thrombectomy 304 305 and poor intra-operative runoff were detected among risk factors for amputation and death in 107 patients with ALI undergoing infrainguinal bypass<sup>16</sup>. Also, any patent pedal outflow was 306 307 a significant predictor for technical success in patients with ALI managed surgically (296 pts) or by endovascular technique (147 pts) in the study of Taha and associates<sup>17</sup>. Failed 308 309 mechanical recanalization of the diffusely occluded infrapopliteal vascular bed influenced the 310 need for thrombolytic therapy, the rate of major bleeding, treatment outcomes, amputation 311 and mortality rates in patients with ALI and SLI<sup>8</sup>.

The greatest mean lesion lengths were reported in the studies of ALI and SLI patients with target occlusions located in the femoropopliteal bypass (32.1; 28.4 cm)<sup>18,19</sup>. In our series, the mean length of the target occlusion was 22.9 cm and 22. 8 % of 316 patients suffered from occluded femoropopliteal bypass.

The comparison between patients with embolic vs. thrombotic cause of arterial occlusions, we documented higher age, higher frequency of female gender, cardiac disease, arrhythmias, ALI, ALI IIB, occlusions of femoropopliteal segment and/or profunda femoris in subjects with embolism. They also presented higher frequency of additional infrapopliteal

13

occlusion, lower number of patent tibial vessels and lower ABI before treatment. Thus,
historical view that embolism produces more severe ischaemia than thrombosis was
confirmed.

323 Thrombosis subgroup presented higher incidence of male gender, smoking history, 324 subacute ischemia, acute ischemia IIA, claudication, tissue defect, femoropopliteal bypass and 325 in-stent occlusions. Furthermore, these patients presented greater mean occlusion length, higher ABI and number of patent calf vessels. Aune and Trippestad<sup>20</sup> reported in their study 326 327 of 272 patients managed by embolectomy (192 pts. with embolism) or bypass (80 pts. with 328 thrombosis), a higher mean age, frequency of female gender and cardiac disease, together 329 with shorter life expectancy in patients with embolism. Kuukasjarvi et al. in their study of 509 ALI patients (without previous reconstructions) from National Vascular Registry<sup>21</sup> detected 330 331 higher frequency of embolism in patients of age 75 or more years and smoking as a risk factor 332 for acute thrombosis. The authors speculated that the worse prognosis (higher amputation 333 rate, mortality rates and necessity for repeated interventions) of patients with acute thrombotic 334 occlusion was associated with advanced atherosclerosis.

Higher age and frequency of hypertension, arrhythmias, embolism, occlusions of femoropopliteal segment and deep femoral artery were associated with female gender. Smoking history, renal insufficiency, tissue defects, thrombosis as a cause of the occlusion and femoropopliteal bypass occlusion were more frequent in patients of male gender. Additionally, we observed statistical trend toward more frequent claudication in the male group.

Similar results can be found in the literature. Braithwaite and colleagues<sup>22</sup> managed 84 elderly patients (75-100 years) with ALI by surgery and/or thrombolysis. Percentage of females was 71.4 % in their series and female preponderance was greatest (84.8 %) in the subgroup selected for immediate embolectomy. Female predominance was detected also in

14

other studies: 57 % in subgroup with embolism<sup>18</sup> and 54 % of 23 268 ALI patients of the 345 National Impatient Sample (NIS)<sup>23</sup>. Kashyap and associates<sup>14</sup> reported increased risk of limb 346 loss with the female gender in 119 ALI patients managed by thrombolysis. Mortality rate was 347 6 % and dying patients were women only. Female gender as a risk associated with limb 348 amputation was detected also by Kuoppala M and colleagues<sup>24</sup>. The NATALI study<sup>25</sup> 349 350 described female gender as a risk factor for mortality and for all and major complications associated with thrombolytic treatment. On the other hand, Eliason JL et al.<sup>23</sup> reported 351 352 decreased risk of amputation in women, in patients with embolectomy, percutaneous 353 transluminal angioplasty and age less than 63 years in NIS patients. The authors did not detect 354 the female preponderance or lower amputation risk in their single institution study (105 355 patients).

356 *CONCLUSION*:

Multisegmental (supratibial plus infrapopliteal) arterial occlusions were documented in 90.6 % of ALI patients and in 78.1 % of SLI patients with threatened lower extremity. The value of ABI related to the number of occluded tibial arteries.

The most frequent locations of supratibial occlusions were femoropopliteal segment (73.1 %) and femoropopliteal bypass (22.8 %) without significant difference in clinical categories. Occlusion locations related to ALI (IIA+IIB) were the aortoiliac segment and/or profunda femoris. Also, more ALI subjects presented additional infrapopliteal occlusion (acute and/or subacute) and lower number of patent tibial arteries and lower ABI.

Anatomically, the important factor related to the ischaemia severity and symptoms duration was the status of infrapopliteal vascular bed. The number of patent or acutely, subacutely and chronically occluded tibial vessels related to individual clinical categories of ALI and SLI and to ABI. This suggests that tibial repefusion can be essential for the salvage of threatened limb and should be always considered.

15

Patients with the most severe ischaemia and immediately threatened extremity (ALI IIB) presented shortest symptoms duration, higher frequency of rest pain, embolism, diabetes, additional acute infrapopliteal occlusion, lower number of patent tibial vessels and lower ABI in comparison with ALI IIA patients. More frequent diabetes can participate on higher number of occluded tibial vessels in this subgroup.

On the other hand, more patients with thrombosis, smoking history, hyperlipidemia, claudication, higher number of patent calf vessels and higher ABI were detected in ALI IIA subgroup.

In comparison with ALI group, the subjects with SLI presented more frequently the thrombosis as a cause of target occlusion, smoking history, claudication, tissue defects, shorter target occlusion, lower number of occluded tibial vessels and higher ABI. Furthermore, they presented younger age, less embolism and arrhythmias, less aortoiliac segment and deep femoral artery occlusions.

383 Embolism as a cause of the supratibial arterial occlusion was associated with higher 384 age, female gender, cardiac disease, arrhythmias, ALI, ALI IIB, femoropopliteal segment and 385 deep femoral artery occlusions, infrapopliteal occlusions, lower ABI and number of patent 386 calf vessels. Higher ischaemia severity in subjects with embolism was not associated only 387 with the fact that embolus suddenly occluded healthy supratibial artery but also with higher 388 frequency of additional infrapopliteal occlusion, profunda femoris occlusion and the higher 389 number of occluded tibial vessels. The data confirmed a historical view that the most severe 390 ischemia occurs with the embolism.

Thrombosis was associated with smoking history, SLI, ALI IIA, claudication, tissue defects, longer target lesion, femoropopliteal bypass occlusion, in-stent occlusion, higher ABI and number of patent calf vessels.

16

- Patients of female gender presented higher age, higher frequency of hypertension,
- 395 arrhythmias, embolism, femoropopliteal and profunda femoris occlusions. Male group
- 396 manifested a higher frequency of smoking history, renal insufficiency, tissue defect,
- 397 thrombosis and femoropopliteal bypass occlusion.
- 398 Grouping the patients categorized in different clinical categories of ALI and SLI can
- 399 affect the treatment outcomes.
- 400
- 401 <u>REFERENCES</u>
- Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of
   peripheral arterial diseas (TASC II). Eur J Vasc Endovasc Surg 2007;33, suppl 1:S1-S75.
- 2. Rutherford RB, Baker JD, Ernst C et al. Recommended standards for reports dealing with
  lower extremity ischemia: Revised version. J Vasc Surg 1997;26:517-538.
- 3. Patel N, Sacks D, Patel RI et al. SCVIR reporting standards for the treatment of acute limb
  ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol
  2001;12:559-570.
- 4. Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for
   percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for
- 411 acute lower-limb ischemia. Cardiovasc Intervent Radiol 2011;34:1123-1136.
- 5. Ouriel K, Veith FJ. Acute lower limb ischemia: determinants of outcome. Surgery
  1998;124:336-342.
- 6. Henke PK. Contemporary management of acute limb ischemia: factors associated with
  amputation and in-hospital mortality. Semin Vasc Surg 2009;22:34-40.
- 7. Dosluoglu HH, Harris LM. Endovascular management of subacute lower extremity
  ischemia. Semin Vasc Surg 2008;21:167-179.
- 418 8. Bulvas M, Sommerová Z, Vaněk I, Weiss J. Prospective single-arm trial of endovascular
- 419 mechanical debulking as initial therapy in patients with acute and subacute lower limb
- 420 ischemia: one-year outcomes. J Endovasc Ther 2019;26:291-301.
- 421 9. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management 422 of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal 423 aortic): executive summary. A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and 424 425 Interventions, Society for Vascular Medicine and Biology, Society of Interventional 426 Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to 427 Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). 428 Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; 429 National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-430 Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-431 1312.
- 432


17

10. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the diagnosis and 433 434 treatment of peripheral artery diseases: document covering atherosclerotic disease of 435 extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The 436 Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European 437 Society of Cardiology (ESC). Eur Heart J 2011;32:2851–2906. 438 439 11. O'Connell JB, Quiňones-Baldrich WJ. Proper evaluation and management of acute 440 embolic versus thrombotic limb ischemia. Semin Vasc Surg 2009;22:10-16. 12. McNamara TO, Gardner KR, Bomberger RA, Greaser LE. Clinical and angiographic 441 442 selection factors for thrombolysis as initial therapy for acute lower limb ischemia. J Vasc 443 Interv Radiol 1995;6(suppl):36S-47S. 444 445 13. Huettl EA, Soulen MC. Thrombolysis of lower extremity embolic occlusions: a study of 446 the results of the Star Registry. Radiology 1995;197:141-145. 447 448 14. Kashyap VS, Gilani R, Bena JF, Bannazadeh M, Sarac TP. Endovascular therapy for 449 acute limb ischemia. J Vasc Surg 2011;53:340-46. 450 451 15. Kasirajan K, Gray B, Beavers FP, Clair DG, Greenberg R, Mascha E, Ouriel K. Rheolytic 452 thrombectomy in the management of acute and subacute limb-threatening ischemia. 453 J Vasc Interv Radiol 2001; 12:413–421. 454 455 16. Marqués de Marino P, Martínez López I, Revuelta Suero S et al. Results of infrainguinal 456 bypass in acute limb ischaemia. Eur J Vasc Endovasc Surg 2016;51:824-30. 457 458 17. Taha AG, Byrne RM, Avgerinos ED, Marone LK et al. Comparative effectiveness of 459 endovascular versus surgical revascularization for acute lower extremity ischemia J Vasc Surg 460 2015;61:147-54. 461 462 18. Hundt W, Kalinowski M, Stamm AC, Portig I, Swaid Z, Dietz C, Geks J, Burbelko M. 463 Combined treatment of subacute and acute synthetic and venous bypass-graft occlusions with 464 percutaneous mechanical thrombectomy and thrombolysis. Eur J Radiol 2013;82:e807-e815. 465 doi: 10.1016/j.ejrad.2013.08.016 466 19. Wissgott C, Kamusella P, Andresen R. Recanalization of acute and subacute venous and 467 synthetic bypass-graft occlusions with a mechanical rotational catheter. Cardiovasc Intervent 468 Radiol 2013;36:936–942. 469

- 20. Aune S, Trippestad A. Operative mortality and long-term survival of patients operated on
  for acute lower limb ischaemia. Eur J Vasc Endovasc Surg 1998;15:143-146.
- 472
- 473 21. Kuukasjarvi P, Salenius J.P and the Finnvasc study group. Perioperative outcome of acute
  474 lower limb ischaemia on the basis of the National Vascular Registry. Eur J Vasc Surg
  475 1994;8:578-583.
- 476
- 477 22. Braithwaite BD, Davies B, Birch PA, Heather BP, Earnshaw JJ. Management of acute leg
  478 ischaemia in the elderly. Brit J Surg 1998;85:217-220.
- 479


18

- 480 23. Eliason JL, Wainess RM, Proctor MC, Dimick JB, Cowan JA et al. A National and single
- 481 institutional experience in the contemporary treatment of acute lower extremity ischemia. Ann
  482 Surg 2003;238:382-390.
- 483 24. Kuoppala M, Franzén S, Lindblad B, Acosta S. Long-term prognostic factors after
- thrombolysis for lower limb ischemia. J Vasc Surg 2008;47:1243-1250.
- 485
- 486 25. Earnshaw JJ, Whitman B, Foy C for the Thrombolysis Study Group. National Audit of
- 487 Thrombolysis for Acute Leg Ischemia (NATALI): Clinical factors associated with early
- 488 outcome. J Vasc Surg 2004;39:1018-25.
- 489



| Characteristics                                   | Summary<br>Statistics | All Subjects                                   | Sub-Acute<br>Ischemia | Acute<br>Ischemia                              | p-value |
|---|-----------------------|--|-----------------------|--|---------|
| Number of patent calf vessels<br>before treatment | n<br>Mean ± SD        | $\begin{array}{c} 316\\ 0.9\pm1.1 \end{array}$ | $114 \\ 1.3 \pm 1.2$  | $\begin{array}{c} 202\\ 0.7\pm1.0 \end{array}$ | <.0001  |
| Patients with no patent tibial vessels            | % (n/N)               | 51.9%<br>(164/316)                             | 33.3%<br>(38/114)     | 62.4%<br>(126/202)                             | 0.0001  |
| Patients with 1 patent tibial vessel              | % (n/N)               | 17.7%<br>(56/316)                              | 22.8%<br>(26/114)     | 14.9%<br>(30/202)                              | 0.0914  |
| Patients with 2 patent tibial vessels             | % (n/N)               | 16.5%<br>(52/316)                              | 21.9%<br>(25/114)     | 13.4%<br>(27/202)                              | 0.0581  |
| Patients with 3 patent tibial vessels             | % (n/N)               | 13.9%<br>(44/316)                              | 21.9%<br>(25/114)     | 9.4% (19/202)                                  | 0.0036  |

**Fig. 1.** ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)



## ABI in Subacute and Acute Ischemia

| SL | (%) | 🗖 A LI | (%) |
|----|-----|--------|-----|
|----|-----|--------|-----|

| Characteristics         | Summary<br>Statistics | All Subjects                                    | Sub-Acute<br>Ischemia                         | Acute Ischemia                                    | p-value |
|-------------------------|-----------------------|---|---|---|---------|
| ABI before<br>treatment | n<br>Mean ± SD        | $\begin{array}{c} 309\\ 0.1\pm 0.2 \end{array}$ | $\begin{array}{c} 108\\ 0.2\pm0.2\end{array}$ | $\begin{array}{c} 201 \\ 0.1 \pm 0.1 \end{array}$ | <.0001  |
| ABI 0-0.1               | % (n/N)               | 57% (176/309)                                   | 31.4% (34/108)                                | 71.2% (143/201)                                   | <.0001  |
| ABI 0.11-0.2            | % (n/N)               | 8.7% (27/309)                                   | 7.6% (8/108)                                  | 9.0% (18/201)                                     | 0.8302  |
| ABI 0.21-0.3            | % (n/N)               | 14.2% (44/309)                                  | 25.7% (28/108)                                | 8.5% (17/201)                                     | 0.0001  |
| ABI 0.31-0.4            | % (n/N)               | 13.9% (43/309)                                  | 23.8% (26/108)                                | 8.0% (16/201)                                     | 0.0002  |
| ABI 0.41-0.5            | % (n/N)               | 4.5% (14/309)                                   | 8.6% (9/108)                                  | 2.5% (5/201)                                      | 0.0236  |
| ABI 0.51-0.6            | % (n/N)               | 1.3% (4/309)                                    | 2.8% (3/108)                                  | 0.5% (1/201)                                      | 0.1245  |
| ABI 0.61-0.7            | % (n/N)               | 0.3% (1/309)                                    | 0% (0/108)                                    | 0.5% (1/201)                                      |         |

**Fig. 2.** Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 - 0.5), SLI is more frequent.




Fig. 3. The number of patent tibial vessels significantly (p<.001) correlates to ABI in SLI patients .

0.139

0.214

0.244

0.346

0.229

37

21

25

24

107

0.160

0.129

0.156

0.150

0.168

0

0

0

0

0

0.420

0.450

0.460

0.600

0.600


0

1

2

3

All Groups



| Breakdown Table of Descriptive Statistics (tibial vessels patent, ABI) |       |     |         |         |         |  |  |
|--|-------|-----|---------|---------|---------|--|--|
| Welch ANOVA test (p<0.001)   |       |     |         |         |         |  |  |
| ALI tibial vessels patent  | ABI   | ABI | ABI ALI | ABI ALI | ABI ALI |  |  |
|  | ALI   | ALI | SD      | Minimum | Maximum |  |  |
|  | Means | Ν   |         |         |         |  |  |
| 0  | 0.032 | 125 | 0.090   | 0       | 0.460   |  |  |
| 1  | 0.150 | 30  | 0.165   | 0       | 0.460   |  |  |
| 2  | 0.151 | 27  | 0.173   | 0       | 0.560   |  |  |
| 3  | 0.149 | 19  | 0.176   | 0       | 0.620   |  |  |
| All Groups   | 0.081 | 201 | 0.140   | 0       | 0.620   |  |  |

**Fig. 4.** Also in ALI patients, the number of patent tibial vessels significantly (p<.001) correlates to ABI.

#### LEGENDS

Fig. 1. ALI dominates in patients with occlusions (complete or segmental) of all tibial vessels, while SLI majority is present in those with 1, 2 or 3 tibial vessels patent. SD - standard deviation, vss-vessel(s)

Fig. 2. Frequency of SLI and ALI in different ABI intervals. ALI predominates in patients with the lowest ABI (range 0-0.1). In subjects with higher ABI (range 0.21 - 0.5), SLI is more frequent.

Fig. 3. The number of patent tibial vessels significantly (p<.001) correlates to ABI in SLI patients.

Fig. 4. Also in ALI patients, the number of patent tibial vessels significantly (p<.001) correlates to ABI.

Table 1. Demography, concomitant disease, ischemia classification and symptoms: SLI vs.

ALI

- Table 2. Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI
- Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB
- Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB
- Table 5. Demographics, concomitant disease, ischemia classification and symptoms: thrombosis vs. embolism
- Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism
- Table 7. Age, concomitant disease, symptoms, ischemia classification, occlusion length and location: female vs. male gender

## Table 1. Demography, concomitant disease, ischaemia classification and symptoms: SLI vs.

## ALI

| Characteristics                         | Summary<br>Statistics             | All Subjects                     | Sub-Acute<br>Ischemia            | Acute Ischemia                               | p-value |
|---|-----------------------------------|----------------------------------|----------------------------------|--|---------|
| Age (years)                             | n<br>Mean ± SD<br>Median<br>Range | $31670.9 \pm 12.071.023.0, 96.0$ | $11467.9 \pm 10.967.031.0, 94.0$ | $202 \\ 72.6 \pm 12.2 \\ 73.0 \\ 23.0, 96.0$ | 0.0005  |
| Male                                    | % (n/N)                           | 58.2% (184/316)                  | 61.4% (70/114)                   | 56.4% (114/202)                              | 0.4079  |
| Diabetes                                | % (n/N)                           | 30.7% (97/316)                   | 28.1% (32/114)                   | 32.2% (65/202)                               | 0.5256  |
| Smoking history                         | % (n/N)                           | 54.4% (172/316)                  | 64.0% (73/114)                   | 49.0% (99/202)                               | 0.0134  |
| Hyperlipidaemia                         | % (n/N)                           | 38.9% (123/316)                  | 41.2% (47/114)                   | 37.6% (76/202)                               | 0.5496  |
| Hypertension                            | % (n/N)                           | 74.7% (236/316)                  | 73.7% (84/114)                   | 75.2% (152/202)                              | 0.7884  |
| Cardiac disease                         | % (n/N)                           | 42.1% (133/316)                  | 35.1% (40/114)                   | 46.0% (93/202)                               | 0.0749  |
| Arrhythmias                             | % (n/N)                           | 25.6% (81/316)                   | 16.7% (19/114)                   | 30.7% (62/202)                               | 0.0071  |
| Cerebrovascular<br>disease              | % (n/N)                           | 25.0% (79/316)                   | 19.3% (22/114)                   | 28.2% (57/202)                               | 0.0809  |
| Malignant disease                       | % (n/N)                           | 7.3% (23/316)                    | 7.9% (9/114)                     | 6.9% (14/202)                                | 0.8226  |
| Renal insufficiency                     | % (n/N)                           | 23.4 % (74/316)                  | 17.5 % (20/114)                  | 26.7 % (54/202)                              | 0.0726  |
| Acute limb<br>ischaemia<br>category IIA | % (n/N)                           | 17.7% (56/316)                   |                                  | 27.7% (56/202)                               |         |
| Acute limb<br>ischaemia category<br>IIB | % (n/N)                           | 46.2% (146/316)                  |                                  | 72.3% (146/202)                              |         |
| Subacute limb<br>ischaemia              | % (n/N)                           | 36.1% (114/316)                  | 100% (114/114)                   |  |         |
| Symptoms duration                       | days                              | 70.9±12.0                        | 44.3±27.3                        | 4.13±4.47                                    | <.0001  |
| Claudication                            | % (n/N)                           | 29.1% (92/316)                   | 53.5% (61/114)                   | 15.3% (31/202)                               | <.0001  |
| Rest pain                               | % (n/N)                           | 74.4% (235/316)                  | 57.9% (66/114)                   | 83.7% (169/202)                              | <.0001  |
| Tissue defect                           | % (n/N)                           | 14.9% (47/316)                   | 22.8% (26/114)                   | 10.4% (21/202)                               | 0.0047  |

## Table 2 Hemodynamics, target occlusion cause and location, patent calf vessels: SLI vs. ALI

| Characteristics                                   | Summary<br>Statistics             | All Subjects   | Sub-Acute<br>Ischemia                              | Acute Ischemia  | p-value |
|---|-----------------------------------|--|--|---|---------|
|   |                                   |  |  |   |         |
| Target occlusion length (mm)                      | n<br>Mean ± SD<br>Median<br>Range | $\begin{array}{c} 316\\ 229.2\pm148.1\\ 200.0\\ 15.0,650.0\end{array}$ | $114 \\ 202.0 \pm 136.7 \\ 150.0 \\ 15.0, 650.0$   | $\begin{array}{c} 202 \\ 244.6 \pm 152.4 \\ 200.0 \\ 20.0, 590.0 \end{array}$ | 0.0159  |
| Target occlusion cause: Embolism                  | % (n/N)                           | 19.0% (60/316)   | 8.8% (10/114)                                      | 24.8% (50/202)  | 0.0005  |
| Target occlusion cause: Thrombosis                | % (n/N)                           | 81.0% (256/316)  | 91.2% (104/114)                                    | 75.2% (152/202)   | 0.0005  |
| Aortoiliac segment occlusion                      | % (n/N)                           | 11.1% (35/316)   | 6.1% (7/114)                                       | 13.9% (28/202)  | 0.0401  |
| Femoropopliteal segment occlusion                 | % (n/N)                           | 73.1% (231/316)  | 78.9% (90/114)                                     | 69.8% (141/202)   | 0.0868  |
| Femoropopliteal bypass occlusion                  | % (n/N)                           | 22.8% (72/316)   | 17.5% (20/114)                                     | 25.7% (52/202)  | 0.1241  |
| Femoro-femoral cross bypass occlusion             | % (n/N)                           | 0.6% (2/316)   | 0  | 1.0% (2/202)  | 0.5373  |
| Leg of bifurcation stentgraft occlusion           | % (n/N)                           | 0.3% (1/316)   | 0  | 0.5% (1/202)  | 1.0000  |
| Ileofemoral bypass occlusion                      | % (n/N)                           | 0.3% (1/316)   | 0.9% (1/114)                                       | 0   | 0.3608  |
| Deep femoral artery occlusion                     | % (n/N)                           | 10.1% (32/316)   | 5.3% (6/114)                                       | 12.9% (26/202)  | 0.0332  |
| In-stent occlusion                                | % (n/N)                           | 23.4% (74/316)   | 21.9 % (24/114)                                    | 24.3 % (49/202)   | 0.6800  |
| Additional infrapopliteal occlusion               | % (n/N)                           | 61.7% (195/316)  | 50.0% (57/114)                                     | 68.3% (138/202)   | 0.0017  |
| Number of patent calf vessels<br>before treatment | n<br>Mean ± SD<br>Median<br>Range | $316 \\ 0.9 \pm 1.1 \\ 0.0 \\ 0.0, 4.0$                                | $     114     1.3 \pm 1.2     1.0     0.0, 3.0   $ | $202 \\ 0.7 \pm 1.0 \\ 0.0 \\ 0.0, 4.0$                                       | <.0001  |
| ABI before treatment                              | n<br>Mean ± SD<br>Median<br>Range | $\begin{array}{c} 309 \\ 0.1 \pm 0.2 \\ 0.0 \\ 0.0, 0.6 \end{array}$   | $108 \\ 0.2 \pm 0.2 \\ 0.3 \\ 0.0, 0.6$            | $\begin{array}{c} 201 \\ 0.1 \pm 0.1 \\ 0.0 \\ 0.0, 0.6 \end{array}$          | <.0001  |

Table 3. Demographics, concomitant disease, symptoms and target occlusion cause: ALI IIA vs. ALI IIB.

|                                       | Summary         |                    |                 |                 |         |
|---------------------------------------|-----------------|--------------------|-----------------|-----------------|---------|
| Characteristics                       | Statistics      | All ALI Subjects   | ALI IIA         | ALI IIB         | p-value |
| Age (years)                           | n               | 202                | 56              | 146             | 0.2113  |
|                                       | Mean ± SD       | $72.6 \pm 12.2$    | $70.8 \pm 12.9$ | $73.2 \pm 11.9$ |         |
|                                       | Median<br>Range | 73.0<br>23.0, 96.0 | 73.0            | 74.0            |         |
|                                       | Tunge           | 25.0, 90.0         | 23.0, 96.0      | 43.0, 96.0      |         |
| Male                                  | % (n/N)         | 56.4% (114/202)    | 62.5% (35/56)   | 54.1% (79/146)  | 0.4079  |
| Diabetes                              | % (n/N)         | 32.2% (65/202)     | 21.4% (12/56)   | 36.3% (53/146)  | 0.0452  |
| Smoking history                       | % (n/N)         | 49.0% (99/202)     | 60.7% (34/56)   | 44.5% (65/146)  | 0.0425  |
| Hyperlipidaemia                       | % (n/N)         | 37.6% (76/202)     | 50.0% (28/56)   | 32.9% (48/146)  | 0.0344  |
| Hypertension                          | % (n/N)         | 75.2% (152/202)    | 71.4% (40/56)   | 76.7% (112/146) | 0.4685  |
| Cardiac disease                       | % (n/N)         | 46.0% (93/202)     | 41.1% (23/56)   | 47.9% (70/146)  | 0.4319  |
| Arrhythmias                           | % (n/N)         | 30.7% (62/202)     | 28.6% (16/56)   | 31.5% (46/146)  | 0.7357  |
| Cerebrovascular<br>disease            | % (n/N)         | 28.2% (57/202)     | 17.9% (10/56)   | 32.2% (47/146)  | 0.0543  |
| Malignant disease                     | % (n/N)         | 6.9% (14/202)      | 5.4% (3/56)     | 7.5% (11/146)   | 0.7615  |
| Renal insufficiency                   | % (n/N)         | 23.4% (74/316)     | 17.5% (20/114)  | 26.7% (54/202)  | 0.0726  |
| Symptoms duration                     | n               | 202                | 56              | 146             | 0.0004  |
| (days)                                | Mean ± SD       | 4.1±4.5            | 6.8±5.3         | 3.1±3.6         |         |
|                                       | Median          | 2.0                | 6.5             | 2.0             |         |
|                                       | Range           | 0.04, 14.0         | 0.08, 14.0      | 0.04, 14.0      |         |
| Claudication                          | % (n/N)         | 15.3% (31/202)     | 39.3% (22/56)   | 6.2% (9/146)    | <.0001  |
|                                       | % (n/N)         |                    |                 |                 |         |
| Rest pain                             | % (n/N)         | 83.7% (169/202)    | 62.5% (35/56)   | 91.8% (134/146) | <.0001  |
| Tissue defect                         | % (n/N)         | 10.4% (21/202)     | 10.7% (6/56)    | 10.3% (15/146)  | 1.000   |
| Target occlusion<br>cause: Embolism   | % (n/N)         | 24.8% (50/202)     | 14.3% (8/56)    | 28.8% (42/146)  | 0.0442  |
| Target occlusion<br>cause: Thrombosis | % (n/N)         | 75.2% (152/202)    | 85.7% (48/56)   | 71.2% (104/146) | 0.0442  |

Table 4. Target occlusion length, occlusion location, patent calf vessels and ABI: ALI IIA vs. ALI IIB

|   | Summary                            |  |  |   |         |
|---|------------------------------------|--|--|---|---------|
| Characteristics                                   | Statistics                         | All Subjects   | ALI IIA                                | ALI IIB                                 | p-value |
| Target occlusion                                  | n                                  | 202  | 56                                     | 146                                     | 0.0938  |
| length (mm)                                       | Mean ± SD                          | $244.6 \pm 152.4$  | $215.5\pm150.2$                        | $255.7 \pm 152.3$                       |         |
|   | Median<br>Range                    | 200.0<br>20.0, 590.0   | 150.0<br>20.0, 550.0                   | 220.0 20.0,<br>590.0                    |         |
| A ( 131   |                                    | · · · · · ·  |  |   | 1.000   |
| Aortoiliac segment<br>occlusion                   | % (n/N)                            | 13.9 %   | 14.3 %                                 | 13.7 %                                  | 1.000   |
|   |                                    | (28/202)   | (8/56)                                 | (20/146)                                |         |
| Femoropopliteal                                   | % (n/N)                            | 69.8%  | 69.6%                                  | 69.9%                                   | 1.000   |
| segment occlusion                                 |                                    | (141/202)  | (39/56)                                | (102/146)                               |         |
| Femoropopliteal                                   | % (n/N)                            | 25.7 %   | 25.0 %                                 | 26.0 %                                  | 1.000   |
| bypass  |                                    | (52/202)   | (14/56)                                | (38/146)                                |         |
| Leg of bifurcation stentgraft                     | % (n/N)                            | 0.5% (1/202)   | 1.8% (1/56)                            | 0.5% (1/202)                            | 0.2772  |
| occlusion   |                                    |  |  |   |         |
| Ileofemoral bypass occlusion                      | % (n/N)                            | 25.7% (52/202)   | 25.0% (14/56)                          | 26.0% (38/146)                          | 1.000   |
| Deep femoral<br>artery occlusion                  | % (n/N)                            | 12.9% (26/202)   | 5.4% (3/56)                            | 15.8% (23/146)                          | 0.0597  |
| In-stent occlusion                                | % (n/N)                            | 24.3% (49/202)   | 33.9% (19/56)                          | 20.5% (30/146)                          | 0.0657  |
| Additional<br>infrapopliteal<br>occlusion         | % (n/N)                            | 68.3% (138/202)  | 57.1% (32/56)                          | 72.6% (106/146)                         | 0.0427  |
| No. of patent calf<br>vessles before<br>treatment | n<br>Mean ± std<br>Median<br>Range | $202 \\ 0.7 \pm 1.0 \\ 0.0 \\ 0.0, 4.0$                              | $56 \\ 1.4 \pm 1.1 \\ 1.0 \\ 0.0, 3.0$ | $146 \\ 0.4 \pm 0.9 \\ 0.0 \\ 0.0, 4.0$ | <.0001  |
| ABI before<br>treatment                           | n<br>Mean ± SD<br>Median<br>Range  | $\begin{array}{c} 201 \\ 0.1 \pm 0.1 \\ 0.0 \\ 0.0, 0.6 \end{array}$ | $550.2 \pm 0.20.20.0, 0.6$             | $146\\0.0\pm 0.1\\0.0\\0.0, 0.4$        | <.0001  |

Table 5. Demographics, concomitant disease, ischaemia classification and symptoms: thrombosis vs. embolism

| Characteristics           | Summary<br>Statistics             | All Subjects                     | Thrombosis                       | Embolism   | p-value |
|---------------------------|-----------------------------------|----------------------------------|----------------------------------|--|---------|
| Age (years)               | n<br>Mean ± SD<br>Median<br>Range | $31670.9 \pm 12.071.023.0, 96.0$ | $25670.2 \pm 11.370.043.0, 96.0$ | $\begin{array}{c} 60 \\ 73.7 \pm 14.2 \\ 76.0 \\ 23.0, 94.0 \end{array}$ | 0.0054  |
| Male                      | % (n/N)                           | 58.2% (184/316)                  | 63.7% (163/256)                  | 35.0% (21/60)  | <.0001  |
| Female                    | % (n/N)                           | 41.8% (132/316)                  | 36.3% (93/256)                   | 65.0% (39/60)  | <.0001  |
| Diabetes                  | % (n/N)                           | 30.7% (97/316)                   | 30.1% (77/256)                   | 33.3% (20/60)  | 0.6425  |
| Smoking history           | % (n/N)                           | 54.4% (172/316)                  | 59.8% (153/256)                  | 31.7% (19/60)  | <.0001  |
| Hyperlipidaemia           | % (n/N)                           | 38.9% (123/316)                  | 39.5% (101/256)                  | 36.7% (22/60)  | 0.7692  |
| Hypertension              | % (n/N)                           | 74.7% (236/316)                  | 74.6% (191/256)                  | 75.0% (45/60)  | 1.0000  |
| Cardiac disease           | % (n/N)                           | 42.1% (133/316)                  | 37.5% (96/256)                   | 61.7% (37/60)  | 0.0008  |
| Arrhythmias               | % (n/N)                           | 25.6% (81/316)                   | 19.5% (50/256)                   | 51.7% (31/60)  | <.0001  |
| Cerebrovascular disease   | % (n/N)                           | 25.0% (79/316)                   | 26.6% (68/256)                   | 18.3% (11/60)  | 0.2458  |
| Malignant disease         | % (n/N)                           | 7.3% (23/316)                    | 7.8% (20/256)                    | 5.0% (3/60)  | 0.5874  |
| Renal insufficiency       | % (n/N)                           | 23.4% (74/316)                   | 23.8% (61/256)                   | 21.7% (13/60)  | 0.8657  |
| Subacute ischaemia        | % (n/N)                           | 36.1% (114/316)                  | 40.6% (104/256)                  | 16.7% (10/60)  | 0.0005  |
| Acute ischaemia           | % (n/N)                           | 63.9% (202/316)                  | 59.4% (152/256)                  | 83.3% (50/60)  | 0.0005  |
| Acute ischaemia class IIA | % (n/N)                           | 27.7% (56/202)                   | 31.6% (48/152)                   | 16.0% (8/50)   | 0.0442  |
| Acute ischaemia class IIB | % (n/N)                           | 72.3% (146/202)                  | 68.4% (104/152)                  | 84.0% (42/50)  | 0.0442  |
| Claudication              | % (n/N)                           | 29.1% (92/316)                   | 32.4% (83/256)                   | 15.0% (9/60)   | 0.0071  |
| Critical limb ischemia    | % (n/N)                           | 23.4% (74/316)                   | 26.6% (68/256)                   | 10.0% (6/60)   | 0.0062  |
| Rest pain                 | % (n/N)                           | 74.4% (235/316)                  | 73.8% (189/256)                  | 76.7% (46/60)  | 0.7436  |
| Tissue defect             | % (n/N)                           | 14.9% (47/316)                   | 17.2% (44/256)                   | 5.0% (3/60)  | 0.0151  |

## Table 6. Target occlusion length and location, ABI and patent calf vessels: thrombosis vs. embolism

| Characteristics                                | Summary<br>Statistics             | All Subjects   | Thrombosis  | Embolism  | p-value |
|--|-----------------------------------|--|---|---|---------|
| Target lesion length (mm)                      | n<br>Mean ± SD<br>Median<br>Range | $316 \\ 229.2 \pm 148.1 \\ 200.0 \\ 15.0, 650.0$                     | $\begin{array}{c} 256 \\ 246.6 \pm 150.4 \\ 220.0 \\ 15.0, 650.0 \end{array}$ | $\begin{array}{c} 60\\ 155.0 \pm 111.7\\ 125.0\\ 20.0, 480.0 \end{array}$ | <.0001  |
| Aortoiliac segment                             | % (n/N)                           | 11.1% (35/316)   | 10.2% (26/256)  | 15.0% (9/60)  | 0.3588  |
| Femoropopl segment                             | % (n/N)                           | 73.1% (231/316)  | 68.0% (174/256)   | 95.0% (57/60)   | <.0001  |
| Femoropopl bypass                              | % (n/N)                           | 22.8% (72/316)   | 27.7% (71/256)  | 1.7% (1/60)   | <.0001  |
| Femo-femoral cross bypass                      | % (n/N)                           | 0.6% (2/316)   | 0.8% (2/256)  |   |         |
| Leg of bifurcation stentgraft                  | % (n/N)                           | 0.3% (1/316)   | 0.4% (1/256)  |   |         |
| Ileofemoral bypass                             | % (n/N)                           | 0.3% (1/316)   | 0.4% (1/256)  |   |         |
| Deep femoral artery                            | % (n/N)                           | 10.1% (32/316)   | 7.0% (18/256)   | 23.3% (14/60)   | 0.0006  |
| In-stent occlusion                             | % (n/N)                           | 23.4% (74/316)   | 27.7% (71/256)  | 5.0% (3/60)   | <.0001  |
| Additional infrapopliteal occlusion            | % (n/N)                           | 61.7% (195/316)  | 59.0% (151/256)   | 73.3% (44/60)   | 0.0403  |
| No. of patent calf vessles before<br>treatment | n<br>Mean ± SD<br>Median<br>Range | $316 \\ 0.9 \pm 1.1 \\ 0.0 \\ 0.0, 4.0$                              | $256 \\ 1.0 \pm 1.1 \\ 1.0 \\ 0.0, 3.0$                                       | $60\\0.4 \pm 0.9\\0.0\\0.0, 4.0$  | <.0001  |
| ABI before treatment                           | n<br>Mean ± SD<br>Median<br>Range | $\begin{array}{c} 309 \\ 0.1 \pm 0.2 \\ 0.0 \\ 0.0, 0.6 \end{array}$ | $250 \\ 0.14 \pm 0.17 \\ 0.0 \\ 0.0, 0.6$                                     | $59 \\ 0.07 \pm 0.14 \\ 0.0 \\ 0.0, 0.5$                                  | 0.0016  |

# Table 7. Age, concomitant disease, symptoms, ischaemia classification, occlusion length and location: female vs. male gender

| Characteristics                     | Summary<br>Statistics             | All Subjects   | Female  | Male   | p-value |
|-------------------------------------|-----------------------------------|--|---|--|---------|
| Age (years)                         | n<br>Mean ± SD<br>Median<br>Range | $31670.9 \pm 12.071.023.0, 96.0$                                     | $132 \\ 75.1 \pm 11.4 \\ 76.5 \\ 23.0, 96.0$                        | $18467.9 \pm 11.567.531.0, 94.0$                 | <.0001  |
| Diabetes                            | % (n/N)                           | 30.7% (97/316)   | 33.3% (44/132)  | 28.8% (53/184)                                   | 0.3903  |
| Smoking history                     | % (n/N)                           | 54.4% (172/316)  | 36.4% (48/132)  | 67.4% (124/184)                                  | <.0001  |
| Hyperlipidaemia                     | % (n/N)                           | 38.9% (123/316)  | 41.7% (55/132)  | 37.0% (68/184)                                   | 0.4147  |
| Hypertension                        | % (n/N)                           | 74.7% (236/316)  | 81.1% (107/132)   | 70.1% (129/184)                                  | 0.0355  |
| Cardiac disease                     | % (n/N)                           | 42.1% (133/316)  | 42.4% (56/132)  | 41.8% (77/184)                                   | 1.0000  |
| Arrhythmias                         | % (n/N)                           | 25.6% (81/316)   | 34.8% (46/132)  | 19.0% (35/184)                                   | 0.0017  |
| Cerebrovascular disease             | % (n/N)                           | 25.0% (79/316)   | 25.0% (33/132)  | 25.0% (46/184)                                   | 1.0000  |
| Malignant disease                   | % (n/N)                           | 7.3% (23/316)  | 6.8% (9/132)  | 7.6% (14/184)                                    | 0.8301  |
| Renal insufficiency                 | % (n/N)                           | 23.4% (74/316)   | 17.4% (23/132)  | 27.7% (51/184)                                   | 0.0429  |
| Acute limb ischaemia category IIA   | % (n/N)                           | 27.7% (56/202)   | 23.9% (21/88)   | 30.7% (35/114)                                   | 0.3420  |
| Acute limb ischaemia category IIB   | % (n/N)                           | 72.3% (146/202)  | 76.1% (67/88)   | 69.3% (79/114)                                   | 0.3420  |
| Claudication                        | % (n/N)                           | 29.1% (92/316)   | 23.5% (31/132)  | 33.2% (61/184)                                   | 0.0785  |
| Critical limb ischaemia             | % (n/N)                           | 23.4% (74/316)   | 21.2% (28/132)  | 25.0% (46/184)                                   | 0.5011  |
| Rest pain                           | % (n/N)                           | 74.4% (235/316)  | 78.8% (104/132)   | 71.2% (131/184)                                  | 0.1509  |
| Tissue defect                       | % (n/N)                           | 14.9% (47/316)   | 9.8% (13/132)   | 18.5% (34/184)                                   | 0.0375  |
| Target occlusion cause: Embolism    | % (n/N)                           | 19.0% (60/316)   | 29.5% (39/132)  | 11.4% (21/184)                                   | <.0001  |
| Target occlusion cause: Thrombosis  | % (n/N)                           | 81.0% (256/316)  | 70.5% (93/132)  | 88.6% (163/184)                                  | <.0001  |
| Target occlusion length (mm)        | n<br>Mean ± SD<br>Median<br>Range | $316229.2 \pm 148.1200.015.0, 650.0$                                 | $132 \\ 221.0 \pm 142.1 \\ 200.0 \\ 20.0, 590.0$                    | $184 \\ 235.1 \pm 152.5 \\ 200.0 \\ 15.0, 650.0$ | 0.5290  |
| Aortoiliac segment                  | % (n/N)                           | 11.1% (35/316)   | 14.4% (19/132)  | 8.7% (16/184)                                    | 0.1453  |
| Femoropopliteal segment             | % (n/N)                           | 73.1% (231/316)  | 79.5% (105/132)   | 68.5% (126/184)                                  | 0.0296  |
| Femoropopliteal bypass              | % (n/N)                           | 22.8% (72/316)   | 14.4% (19/132)  | 28.8% (53/184)                                   | 0.0027  |
| Femo-femoral cross bypass           | % (n/N)                           | 0.6% (2/316)   | 0.8% (1/132)  | 0.5% (1/184)                                     | 1.0000  |
| Leg of bifurcation stentgraft       | % (n/N)                           | 0.3% (1/316)   |   | 0.5% (1/184)                                     | 1.0000  |
| Ileofemoral bypass                  | % (n/N)                           | 0.3% (1/316)   |   | 0.5% (1/184)                                     | 1.0000  |
| Deep femoral artery                 | % (n/N)                           | 10.1% (32/316)   | 15.2% (20/132)  | 6.5% (12/184)                                    | 0.0142  |
| In-stent occlusion                  | % (n/N)                           | 23.4% (74/316)   | 24.2% (32/132)  | 22.8% (42/184)                                   | 0.7888  |
| Additional infrapopliteal occlusion | % (n/N)                           | 61.7% (195/316)  | 62.9% (83/132)  | 60.9% (112/184)                                  | 0.7266  |
| Number of patent calf vessels       | n<br>Mean ± SD<br>Median<br>Range | $3160.9 \pm 1.10.00.0, 3.0$  | $ \begin{array}{c} 132\\ 0.9 \pm 1.1\\ 0.0\\ 0.0, 3.0 \end{array} $ | $184 \\ 1.0 \pm 1.1 \\ 0.0 \\ 0.0, 3.0$          | 0.6844  |
| ABI before treatment                | n<br>Mean ± SD<br>Median<br>Range | $\begin{array}{c} 309 \\ 0.1 \pm 0.2 \\ 0.0 \\ 0.0, 0.6 \end{array}$ | $129 \\ 0.12 \pm 0.16 \\ 0.0 \\ 0.0, 0.6$                           | $180\\0.14\pm 0.17\\0.0\\0.0, 0.6$               | 0.2715  |